Register to chat with like-minded investors on our interactive forums.
MultiCell Technologies, Inc. (MCET) is a biopharmaceutical company, engaged in the research, development, and commercialization of therapeutic products by using its immune system modulation technologies. The company focuses on the research and development of therapeutics that target degenerative neurological diseases, including multiple sclerosis and cancer.
Its product pipeline includes MCT-125, a phase-2 therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double standard RNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; MCT-475, a discovery stage antibody therapeutic candidate used in combination with dsRNA for the treatment of solid tumor cancers, and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers.
Clearly this company has quite a few products, that if successful, will allow the company to thrive in the future. Of course, the trick is getting there. As the company only has 2 employees, investors will need to be patient. But investors have already seen a nice uptick in the share price over the past week. On February 19th, the company was trading for under .003 and since then, the company has spiked higher than .0055, nearly hitting a double at .006.
It appears that the stock is gaining momentum. If the company is able to back up the technical momentum with a solid press releases, the fireworks may start.
